Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 15: 931-939, 1969;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Belfield, A.
Right arrow Articles by Goldberg, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belfield, A.
Right arrow Articles by Goldberg, D. M.

Clinical Chemistry, Vol 15, 931-939, Copyright © 1969 by the American Association for Clinical Chemistry

Application of a Continuous Spectrophotometric Assay for 5'Nucleotidase Activity in Normal Subjects and Patients with Liver and Bone Disease

Alan Belfield 1 and David M. Goldberg 1

1 Department of Chemical Pathology, The Royal Hospital, Sheffield 1, England.

Serum 5'nucleotidase activity has been measured by a coupled kinetic assay in which adenosine formed by hydrolysis of adenosine 5'-monophosphate in the presence of 150-fold excess of beta-glycerophosphate is converted to inosine by adenosine deaminase, with a consequent decrease in absorbance at 265 nm. The method gives activity in proportion to enzyme concentration so long as the rate of decrease of absorbance at 265 nm does not exceed 0.025/min, and not more than 30% of the substrate is consumed. The normal range established in 517 healthy adults was 0-15 mU/ml. A significant correlation between enzyme activity and age was found in females but not in males. Raised levels of 5'nucleotidase activity were found in 92% of patients with obstructive jaundice, 70% of patients with parenchymal liver disease, 81% of patients with hepatic metastases, and 11% of patients with bone disease. The estimation is useful in aiding the elucidation of raised serum alkaline phosphatase activity, and is of value as a liver function test, but is not as frequently increased as alkaline phosphatase in all classes of hepatobiliary disease.

Submitted on October 25, 1968
Accepted on November 23, 1968




The following articles in journals at HighWire Press have cited this article:


Home page
 Mol. Pharmacol.Home page
K. Choi, E. Mollapour, J. H. Choi, and S. B. Shears
Cellular Energetic Status Supervises the Synthesis of Bis-Diphosphoinositol Tetrakisphosphate Independently of AMP-Activated Protein Kinase
Mol. Pharmacol., August 1, 2008; 74(2): 527 - 536.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. Rej
Clinical Chemistry through Clinical Chemistry: A Journal Timeline
Clin. Chem., December 1, 2004; 50(12): 2415 - 2458.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
F. Pagani and M. Panteghini
5'-Nucleotidase in the Detection of Increased Activity of the Liver Form of Alkaline Phosphatase in Serum
Clin. Chem., November 1, 2001; 47(11): 2046 - 2048.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1969 by the American Association for Clinical Chemistry.